# **Key Investor Information**



This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

## First Trust NYSE Arca Biotechnology UCITS ETF

A sub-fund of First Trust Global Funds plc (the "Company")

First Trust Global Portfolios Management Limited is the manager of the Company (the "Manager")

ISIN: IEOOBLOLOH60

Share class: Class A USD ACC

## **Objective and Investment Policy**

**Objective:** The fund seeks to provide investors with investment results that correspond generally to the price and yield of an equity index called the NYSE Arca Biotechnology Index (the "Index").

**Investment Policy:** The fund invests primarily in equity securities that are included in the Index. The fund attempts to replicate, before fees and expenses, the performance of the Index.

The Investment Manager will seek to do this by trying to replicate the Index by holding in similar proportions the equity securities in the Index. This Fund may, where direct investment in a constituent of the Index is not possible, invest in depository receipts to gain exposure to the security and may also invest in money market instruments, short-term instruments and other eligible Funds. The Investment Manager will regularly monitor how closely the Fund tracks the Index. It is expected that the level of tracking error will be 0-2% in normal market conditions.

The Fund is passively managed and has an index replicating objective.

For details of the exact composition of the Index, please see the following address: https://www.theice.com/market-data/indices/equity-indices/ucits.


For more information about the investment policy, see "Investment Policy" in the Fund's section on supplement available at www.ftglobalportfolios.com.

You may sell your shares usually on each business day (a day on which the London Stock Exchange is open) by sending your request to the administrator.

Income is reinvested into the Fund for this share class.

**Recommendation:** this Fund may not be appropriate for investors who plan to withdraw their money within the short term.

### **Risk and Reward Profile**



Potentially lower reward

Potentially higher reward

The risk category is based on simulated and historical data and may not be a reliable indicator of the future risk profile of the Fund. The risk category shown is not guaranteed and may change over time.

The indicator is designed to help investors understand the uncertainties for both loss and for growth that may affect their investment. The lowest category does not mean that the investment is risk free.

The Fund is ranked at 6 because funds of this type have experienced high rises and falls in value in the past.

The following risks are materially relevant to the Fund which may not be adequately captured by the indicator:

The Fund may not achieve its investment objective and the value of shares in the Fund may fall.

The Fund invests in biotechnology and pharmaceutical companies, which are subject to changing government regulation which could have a negative effect on the price, profitability and availability of their products and services. Biotechnology and pharmaceutical companies face increasing competition from generic drugs, termination of their patent protection and technological advances which render their products or services obsolete. The research and development costs required to bring a drug to market are substantial and may include a lengthy review by the government, with no guarantee that the product will ever be brought to market or show a profit. Many of these companies may not offer certain drugs or products for several years, and as a result, may have significant losses of revenue and earnings.

There is no assurance that the Index will continue to be calculated and published on the basys described in the Prospectus. In addition, the fund's return may not match the return of the Index.

See also the description of the risks applicable to the Fund in "Risk Factors" in the Fund's Prospectus and supplement thereto.



## Charges

The charges you pay are used to pay the costs of running the fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

One-off charges taken before or after you invest	
Entry charge	None*
Exit charge	None*

This is the maximum that might be taken out of your money before it is invested or before the proceeds of your investments are paid out.

Charges taken from the fund over a year		
Ongoing charges	0.60%	
Charges taken from the fund under	s taken from the fund under certain specific conditions	
Performance fee	None	

<sup>\*</sup>Not applicable to secondary market investors. Investors dealing on a stock exchange will pay fees charged by their stock brokers. Such charges are publicly available on exchanges on which the shares are listed and traded, or can be obtained from stock brokers.

Any entry and exit charges shown are maximum figures, and in some cases investors may pay less. You can find out the actual charges from your financial adviser or distributor.


A switching charge of up to 3% may be payable for switching shares (except in the case of an entry/exit charge paid by the fund when buying or selling units in another sub-fund).

In the event that the Fund's operational expenses exceed the stated ongoing charges figure of 0.60%, the investment Manager shall discharge any excess out of its own assets.

The ongoing charges figure is based on the fund's annual management fee, whereby the Investment Manager shall be responsible for the fund's operational expenses.

For more information about charges, please see "Fees, Costs and Expenses" in the Prospectus.

## **Past Performance**



- Class A Accumulation (%)

- The fund was approved in 2019.
- Past performance is not a reliable guide to future performance.

#### **Practical Information**

Investment Manager: First Trust Advisors L.P.

Depositary: The Bank of New York Mellon SA/NV, Dublin Branch

Prospectus and Fund Information: Information about the umbrella First Trust Global Funds plc, its sub-funds and available share classes, including the Prospectus and the latest annual and semi-annual reports of the umbrella, can be obtained in English and free of charge at www.ftglobalportfolios.com.

Share Prices/NAV: The share price is published daily and is available, along with any indicative net asset value, online at www.ftglobalportfolios.com and on www.bloomberg.com.

Tax Treatment: The fund is subject to tax laws and regulations in Ireland. This may have an impact on your personal tax position. Consequently, you should seek independent advice from your tax adviser.

Responsibility for Information: The Manager may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the Prospectus for the Company.

Umbrella Fund: The fund is a sub-fund of the Company which is an umbrella fund with segregated liability between sub-funds. This means that the assets and liabilities of each sub-fund are segregated by law.

**Switching:** Subject to the prior approval of the directors of the Company, you may switch your investment into shares of another sub-fund of the Company. For further details please see the section "Conversion of Shares" in the fund's Prospectus. A charge will be applied if you choose to switch (see above under "Charges").

Remuneration Policy: Information on the current remuneration policy of the Company and the Manager, including a description of how remuneration and benefits are calculated and the identity of persons responsible for awarding the remuneration and benefits is available at https://www.ftglobalportfolios.com/Content/UCITS REMUNERATION POLIC Y. A paper copy of the information is available free of charge upon request from the Manager.

<sup>\*</sup>Authorised participants dealing directly with the fund will pay related transaction costs. Authorised participants switching between the fund and other funds within the Company will be subject to a switching fee of up to 3% of the Net Asset Value per share.